<DOC>
	<DOCNO>NCT01807741</DOCNO>
	<brief_summary>The purpose study compare asenapine placebo treatment depression associate bipolar disorder , type I eight week . We hypothesize patient show significantly great improvement asenapine placebo eight week treatment .</brief_summary>
	<brief_title>Asenapine Bipolar Depression</brief_title>
	<detailed_description>86 patient episode major depression associate bipolar disorder , type I recruit two site study fifteen month . Medication administer double-blind manner . Patients receive asenapine ( placebo ) begin day 0 5 mg bid . Dose may increase 10 mg bid adjust base clinical response . Patients evaluate blinded ( treatment status ) rater . Patients see rating obtain baseline ( day 0 ) day 7 , 14 , 28 , 42 , 56 ( termination study ) . Adverse event evaluate well .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Meet criterion bipolar depression base MINI confirmation previous manic mixed episode 1855 year age Female patient must use medically accept mean contraception ( e.g . oral contraceptive , DepoProvera , abstinence ) Each patient must understand nature study must provide write informed consent Patients must diagnosis bipolar disorder , type I currently display acute depressive episode determine M.I.N.I . ( Sheehan et al , 1998 ) Patients must baseline ( day 0 ) MADRS score â‰¥26 Current episode depression must persist least one month six month study entry Subjects fluent English Female patient either pregnant lactating Clinically significant unstable hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , immunologic , hematologic systemic medical condition Any history current past diabetes treat pharmacological intervention Neurological disorder include epilepsy , stroke , severe head trauma Clinically significant laboratory abnormality , follow test : CBC differential , electrolytes , BUN , creatinine , hepatic transaminase , lipid profile , fast glucose , urinalysis , thyroid index EKG Depression due general medical condition substanceinduced depression ( DSMIV ) Mental retardation ( IQ &lt; 70 ) Meeting criterion mixed episode , define Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) History hypersensitivity intolerance asenapine Prior history asenapine nonresponse DSMIV substance ( except nicotine caffeine ) dependence within past 3 month Judged clinically suicidal risk ( define active suicidal ideation , intent plan , serious suicide attempt within 30 day , baseline MADRS suicide score &gt; 4 ) Participation clinical trial another investigational drug within 1 month ( 30 day ) prior study entry Failure current depressive episode respond two pharmacological intervention Treatment injectable depot neuroleptic within less one dosing interval depot neuroleptic injection day 0 Schizophrenia psychotic disorder ( include schizophreniform disorder , schizoaffective disorder , delusional disorder , brief psychotic disorder , share psychotic disorder , psychotic disorder due general medical condition , substanceinduced psychotic disorder , psychotic disorder otherwise specify ) define DSMIV Major depressive disorder , dysthymic disorder , depressive disorder otherwise specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>